Jignesh Patel

Our research team at King’s College Hospital is looking for mothers who are up to 3 months post delivery for a research study aiming to find out whether new oral blood thinning medications pass into human breast milk. The risk of developing blood clots is increased in women following the birth of a baby. Mothers who are at high risk of getting these clots or already have these clots are given blood thinning medications for at least 7 days after delivery and sometimes for up to 6 weeks. Currently, only traditional blood thinning medicines (heparins and warfarin) can be prescribed to breastfeeding mothers as they are known to be safe during breastfeeding period. Many women find these medicines inconvenient, because they are required to inject heparins themselves at home or attend the clinic frequently for the monitoring of warfarin. In recent years, new blood thinning drugs, such as edoxaban and rivaroxaban, have become available in the UK. They can be taken as tablets and require no monitoring. However, it is not known whether these drugs pass into human breast milk in significant amounts. The purpose of our research study is to investigate whether edoxaban or rivaroxaban pass into human breast milk, which will help to find out if these drugs could be used instead of heparin injections or warfarin for breastfeeding mothers. You may be eligible to participate if you: • Are breastfeeding currently or able to express breastmilk and, • Within 12 weeks of delivery Study participation involves: • Eligibility screening, which can be done at your home • Taking the blood thinning medication allocated once a day for 3 days and having blood tests and providing breastmilk for up to 6 days of the trial. • Stop breastfeeding your baby for the time you take part in the trial. For this study, we are aiming to recruit 12 women in total. As a way of thanks for participation in the study and for your time, you will receive £300 For more information please contact: [email protected] or 07984949011 New Horizons PIL v1.6.pdf

Our team at King's College Hospital is still recruiting volunteers who have recently or are expecting their baby and might be interested in our research study. Please see attached poster for details. volunteers are given £300 for taking part. Please contact Jignesh Patel (07984 94 9011 / [email protected]) if interested. Jignesh Patel King's College Hospital Poster for New Horizons recuritment v1.0 05062023 - newborns final.pdf

Our team at King's College Hospital are still looking for women who have given birth within the last 8 weeks and breastfeeding and interested to take part in our study. See attached poster for more details. Many thanks, Jignesh [email protected] Poster for New Horizons recuritment v2.0 19092022.pdf

Have you recently delivered your baby and are you breastfeeding currently? Our research team in the Thrombosis Centre at King’s College Hospital is looking for breastfeeding mothers for a research study aiming to find out whether new oral blood thinning medications pass into human breast milk. The risk of developing blood clots is increased in women following the birth of a baby. Mothers who are at high risk of getting these clots or already have these clots are given blood thinning medications for at least 7 days after delivery and sometimes for up to 6 weeks. Currently, only traditional blood thinning medicines (heparins and warfarin) can be prescribed to breastfeeding mothers as they are known to be safe during breastfeeding period. Many women find these medicines inconvenient, because they are required to inject heparins themselves at home or attend the clinic frequently for the monitoring of warfarin. In recent years, new blood thinning drugs, such as edoxaban and rivaroxaban, have become available in the UK. They can be taken as tablets and require no monitoring. However, it is not known whether these drugs pass into human breast milk in significant amounts. The purpose of our research study is to investigate whether edoxaban or rivaroxaban pass into human breast milk, which will help to find out if these drugs could be used instead of heparin injections or warfarin for breastfeeding mothers. You may be eligible to participate if you: • Are breastfeeding currently and, • Within 8 weeks of delivery Study participation involves: • Eligibility screening, which can be done at your home • Taking the blood thinning medication allocated once a day for 3 days and having blood tests and providing breast milk for up to 6 days of the trial. • Stop breastfeeding your baby for the time you take part in the trial. For this study, we are aiming to recruit 12 women in total. As a way of thanks for participation in the study and for your time, you will receive £300 For more information please contact: [email protected] or 07984949011